Basic Information
Ngenla
Regulatory Information
EMEA/H/C/005633
Authorised
February 14, 2022
December 16, 2021
5
December 5, 2022
Company Information
Belgium
Boulevard de la Plaine 17 1050 Bruxelles
Pfizer Europe MA EEIG
Drug Classification
Orphan MedicineAdditional Monitoring
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Indicated for the long-term treatment of paediatric patients with growth disturbance due to insufficient secretion of growth hormone
Overview Summary
Ngenla is a medicine used to treat children and adolescents who are not growing at the normal rate as a result of growth hormone deficiency (lack of natural growth hormone). It is given to patients from 3 years of age. Ngenla contains the active substance somatrogon.